We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avery Dennison (AVY) & BD Launch New Vascular Dressings
Read MoreHide Full Article
Avery Dennison Corporation’s (AVY - Free Report) Vancive Medical Technologies business, in association with Becton, Dickinson and Company (BDX - Free Report) (BD), has launched a line of transparent vascular dressings with chlorhexidine gluconate (CHG) antimicrobial preservative. The dressings will enhance patient care and aid easy application and removal for clinicians.
The combination of BD’s vascular access expertise, infection prevention expertise from the CareFusion acquisition and CHG adhesive technology from Avery Dennison’s Vancive Medical Technologies will create a powerful solution for a new vascular access product.
The new BD ChloraShield dressings, which feature BeneHold CHG, an innovative adhesive technology from Vancive Medical Technologies, comfortably secure the dressing to the skin, absorbing fluids and protecting the area from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth, making them apt for catheter insertion sites.
This collaboration brings together complementary expertise from both companies. BD ChloraShield dressings are available in a variety of designs including bordered and non-bordered as well as sizes commonly used for peripheral IVs and PICCs.
BD and Vancive Medical Technologies will showcase the new BD ChloraShield dressings in booth #423 at the 30th annual Association for Vascular Access Conference, being held from Sep 16−19 in Orlando, FL.
Notably, Avery Dennison’s Vancive Medical Technologies business reported solid margin expansion in the second quarter of 2016. The company remains focused on its product pipeline and recently reestablished the organizational link between its Vancive and performance tapes business.
In the long term, these actions, combined with strong growth from the new product platform, should help to deliver consistent organic growth and double-digit margins in this business.
Avery Dennison currently holds a Zacks Rank #2 (Buy).
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Avery Dennison (AVY) & BD Launch New Vascular Dressings
Avery Dennison Corporation’s (AVY - Free Report) Vancive Medical Technologies business, in association with Becton, Dickinson and Company (BDX - Free Report) (BD), has launched a line of transparent vascular dressings with chlorhexidine gluconate (CHG) antimicrobial preservative. The dressings will enhance patient care and aid easy application and removal for clinicians.
The combination of BD’s vascular access expertise, infection prevention expertise from the CareFusion acquisition and CHG adhesive technology from Avery Dennison’s Vancive Medical Technologies will create a powerful solution for a new vascular access product.
The new BD ChloraShield dressings, which feature BeneHold CHG, an innovative adhesive technology from Vancive Medical Technologies, comfortably secure the dressing to the skin, absorbing fluids and protecting the area from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth, making them apt for catheter insertion sites.
Avery Dennison Price
Avery Dennison Price | Avery Dennison Quote
This collaboration brings together complementary expertise from both companies. BD ChloraShield dressings are available in a variety of designs including bordered and non-bordered as well as sizes commonly used for peripheral IVs and PICCs.
BD and Vancive Medical Technologies will showcase the new BD ChloraShield dressings in booth #423 at the 30th annual Association for Vascular Access Conference, being held from Sep 16−19 in Orlando, FL.
Notably, Avery Dennison’s Vancive Medical Technologies business reported solid margin expansion in the second quarter of 2016. The company remains focused on its product pipeline and recently reestablished the organizational link between its Vancive and performance tapes business.
In the long term, these actions, combined with strong growth from the new product platform, should help to deliver consistent organic growth and double-digit margins in this business.
Avery Dennison currently holds a Zacks Rank #2 (Buy).
Other well-ranked stocks in the same sector include ACCO Brands Corporation (ACCO - Free Report) and AO Smith Corp. (AOS - Free Report) , both carrying the same Zacks Rank as Avery Dennison. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>